Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

GVK Biosciences

Request full access

Home | GVK BIO | CRDO | Beyond Contract Research Organization

IndiaFounded 2001Biotech & Life Sciences

About GVK Biosciences

GVK Biosciences, now rebranded as Aragen Life Sciences, is a global contract research, development, and manufacturing organization (CRDMO) established in 2001. Initially founded by Gunupati Venkata Krishna Reddy as part of the GVK Group, a diversified Indian conglomerate, the company began its journey with an informatics division. A significant milestone occurred in 2004 with the entry of D.S. Brar, former CEO of Ranbaxy Laboratories, as promoter and chairman, steering the company's focus on the life sciences R&D value chain. In 2021, coinciding with its 20th anniversary and an investment from Goldman Sachs, GVK BIO rebranded to Aragen Life Sciences to better position itself as a global solutions partner for the biopharma industry.

The company operates on a fee-for-service and full-time equivalent (FTE) based business model, providing integrated services to a diverse client base of over 450 companies that includes large pharmaceutical corporations, biotechnology firms, agrochemical companies, and animal health organizations. With a significant portion of its revenue derived from clients in the US and Europe, Aragen functions as a key partner in the drug development lifecycle. Its business is structured to assist clients in bringing their products to market more efficiently by offering solutions across both small and large molecule platforms. This dual capability was significantly enhanced by the 2014 acquisition of Aragen Bioscience, a US-based preclinical CRO specializing in large-molecule biologics services.

Aragen provides a comprehensive suite of services spanning the entire drug development continuum. This includes early-stage discovery services like medicinal chemistry and biologics, which constituted approximately 65% of its revenue in fiscal 2023. The company also offers development and manufacturing services for drug substances, process research and development, and formulation development. A notable offering is its informatics division, which provides proprietary bio/chemical databases like GOSTAR and IT solutions for data management and analytics to accelerate drug discovery. With a global team of over 4,000, including more than 400 PhDs, Aragen operates across multiple sites in India and the United States, positioning itself as a strategic partner for advancing healthcare solutions from concept to commercialization.

Source: Dealroom company data

At a glance

Status
Operational
Employees
1,575
Open positions
None listed
Dealroom signal
27.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Analytics, Biotechnology, Biotech and Pharma, Hard Tech
Business model
Manufacturing
Client focus
B2B
Investment activity
2 companies, latest Nov 2014
Capital deployed
—
Preferred round
ACQUISITION

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SECONDARYOther financing May 2021 $0 — Undisclosed —
SECONDARYOther financing Dec 2015 $25M — Chrys Capital —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

GVK Biosciences website traffic

Latest recorded traffic for GVK Biosciences is 320 monthly website visits, up 60% over the last three months. GVK Biosciences's team grew 0% over the past year.

Latest monthly visits320 3-month web change+60% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

GVK Biosciences in its local ecosystem

Live from Dealroom

The GVK Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later2 investors entered at this stage

Other known investors1 additional known investor

Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇮🇳 India HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about GVK Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See GVK Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.